Intervacc has begun U.S. safety trials for its equine strangles vaccine Strangvac, initiating vaccinations on Dec. 15, 2025, in a study of about 600 horses across four states in line with USDA rules, with efficacy studies planned for the second half of 2026; U.S. market authorization—targeting roughly 10 million horses—is a company priority. The move marks a key regulatory milestone for a product already approved and launched across the EU, the U.K. and several European markets and, if approved, would materially expand Intervacc’s commercial addressable market.
Intervacc announced the start of U.S. clinical safety studies for its equine strangles vaccine Strangvac, with vaccinations initiated on December 15, 2025. The safety trial will enroll approximately 600 horses across four states under USDA regulations, and the company plans to commence efficacy studies in the second half of 2026. Strangvac is already approved and launched in multiple European markets (EU, UK, Iceland, Norway, Liechtenstein and named EU countries), and management frames U.S. market authorization as a top priority given an addressable population of about 10 million horses. A U.S. approval would materially expand the commercial opportunity and validate the product beyond Intervacc’s current European footprint. Near-term value drivers are execution of the multi-state safety study, timely start of efficacy trials in H2 2026, and favorable FDA/USDA interactions; risks include trial operational delays, regulatory hurdles and the binary nature of approval. Market signals are mildly positive (sentiment score 0.32) with modest projected market impact (0.3), implying measured investor optimism but continued uncertainty until efficacy data and regulatory milestones arrive.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.32
